There have been several HIV care guideline and associated resource material updates this Fall:
Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and the Interventions to Reduce Perinatal HIV Transmission in the United States: The “Recommendations for Use of Antiretroviral Drugs during Pregnancy” and “Table 6: What to Start: Initial Combination Regimens for Antiretroviral Naive-Pregnant Women” sections were updated to include new data and publications where relevant. Additionally, “Table 8: Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy” and “Appendix B: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy” sections have been updated with new data about tenofovir disoproxil fumarate. Click here to see a full list of changes to the guidelines.
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV: The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents has released an updated version of the guidelines with updates to the “What to Start”, “What Not to Use”, “HBV/HIV Coinfection”, “HCV/HIV Coinfection”, “Adherence to Antiretroviral Therapy”, and “Drug Interaction” sections. Additionally, a new table on ARV options for patients experiencing virologic failure, results from clinical trials using two-drug maintenance therapy for virally suppressed patients, and the use of People-First Language has been added to the guidelines. Click here to see a full list of changes to the guidelines.
Also available is an updated ARV therapy pocket guide created by the Florida North AIDS Education and Training Center reflecting recent updates made to the treatment guidelines. Click here to access the updated treatment pocket book.
Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: The Candida section of these guidelines was updated to include isavuconazole as a treatment option for patients with uncomplicated esophageal candidiasis, to highlight the results of a study describing the complications from fluconazole use during pregnancy, and to incorporate statements regarding the occurrence of infections by non-albicans Candida strains, the presence of drug-drug interactions and absorption considerations with posaconazole, and the importance of ART/immune restoration in preventing mucosal candidiasis. Click here to see a full list of changes to the guidelines.